Concomitant HPV Vaccination and HPV Screening HPV Infection and Cervical Cancer in Sweden

NCT ID: NCT04910802

Last Updated: 2021-09-16

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE4
• Total Enrollment: 150000 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-05-03
• Study Completion Date: 2027-12-31

Brief Summary

The study aims to evaluate whether organised, concomitant HPV vaccination and HPV screening offered to all resident women aged 22-27 will result in a more rapid elimination of HPV infection in Sweden. This objective will be examined at the population level.

Detailed Description

In Sweden, 150 women die of and 550 women are diagnosed with cervical cancer each year. The average age at diagnosis is about 55 years and every third woman is under 40 years of age. World-wide, there half a million new cases of cervical cancer each year. The underlying cause of cervical cancer is a human papillomavirus (HPV), an infection that can be prevented by vaccination. The first-generation vaccine protects against HPV infection of the two types (16 and 18) that cause to about 70% of all cervical cancer. Since 2015, a second-generation vaccine (Gardasil 9, Sanofi Pasteur MSD SNC) has been available that provides protection against 9 HPV types of which 7 types (16, 18, 31, 33, 35, 45, 52 and 58) cause 90% of all cervical cancer.

In 2016, the World Health Organization (WHO) called on the countries of the world to eliminate cervical cancer as a public health problem. On 17 November 2020, all 194 WHO member states adopted a global strategy to increase the rate of elimination of cervical cancer. The strategy involves three main actions: vaccination, screening, and treatment. In Sweden, girls have been offered school-based vaccination against HPV with Gardasil 4 since 2012. Starting in the autumn of 2020, schoolboys have also been offered vaccination. Since 2019, the second-generation vaccine has been used in the school-based vaccination program. Sweden's vaccination strategy means that the virus will be eliminated among individuals born in 2007 and beyond. It will thus take another 20 years before Sweden can stop the infection in Sweden. Today, the infection continues to spread only among young adults. Studies have shown that vaccination up to age 26 can be effective and within the European Union, 10 out of 29 countries have a so-called catch-up on vaccination program targeting women over the age of 20 but such a catch-up has not been formally introduced in Sweden.

The overall goal is to investigate whether offering women ages 22-26 years vaccination with Gardasil 9 in connection with screening may involve a faster eradication of cervical cancer as a public health problem in Sweden. A regional pilot study will be conducted in 2021 followed by a subsequent scale-up to other regions.

Conditions

HPV Infection; CIN 2/3; Cervical Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

HPV-vaccination

Women ages 22-26 will be offered concomitant vaccination (1 dose of Gardasil9) and HPV screening. A second dose of Gardasil9 will be administered 3 years later.

Group Type: EXPERIMENTAL

Gardasil9

Intervention Type: BIOLOGICAL

Concomitant vaccination and HPV screening. Gardasil9 will be administered using standard dosage. 1 dose at recruitment and the 2nd dose 3 years later.

Interventions

Gardasil9

Concomitant vaccination and HPV screening. Gardasil9 will be administered using standard dosage. 1 dose at recruitment and the 2nd dose 3 years later.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Eligible women will include resident women within the age range of 22-26, who have not opted out of the screening program and who consent to participate in the study.

Women who respond to the invitation and attend screening will be screened with HPV testing by the current routine practise. Women who consent to participate will also be offered HPV vaccination. The HPV vaccine (Gardasil 9) will be offered regardless of whether the woman reports having had prior vaccination with a first-generation vaccine (Gardasil 4) and regardless of screening test result.

Exclusion Criteria

1. Known history of severe allergic reaction or hypersensitivity to any of the components of the HPV vaccine.For GARDASIL 9: Amorphous aluminium hydroxyphosphate sulphate adjuvant, Sodium chloride, L-histidine, Polysorbate 80 or Sodium borate

2. Known history of immune-related disorders

3. Current acute severe febrile illness, except for minor infections such as a cold, mild upper respiratory infection or low-grade fever.

4. Administration of immunoglobulin or blood-derived products within 6 months prior to scheduled HPV vaccine first dose

5. Current pregnancy (reported)

6. Women with a total hysterectomy

• Minimum Eligible Age: 22 Years
• Maximum Eligible Age: 27 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Karolinska University Hospital

OTHER

Sponsor Role: collaborator

Miriam Elfström

OTHER_GOV

Sponsor Role: lead

Responsible Party

Miriam Elfström

Chief development officer

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Joakim Dillner, MD, PhD

Role: STUDY_DIRECTOR

Karolinska University Hospital Laboratory

Locations

Cancer prevention, screening, and counseling unit, Regional Cancer Center of Stockholm-Gotland

Stockholm, , Sweden

Site Status: RECRUITING

Countries

Sweden

Central Contacts

Miriam Elfström, PhD

Role: CONTACT

miriam.elfstrom@sll.se

+46703816277

Helena Andersson, PhD

Role: CONTACT

helena.t.andersson@sll.se

+46768871126

Facility Contacts

Malin Vikström, BSN

Role: primary

malin.vikstrom@sll.se

+46(0)8-123 131 14

References

Arroyo Muhr LS, Gini A, Yilmaz E, Hassan SS, Lagheden C, Hultin E, Garcia Serrano A, Ure AE, Andersson H, Merino R, Elfstrom KM, Baussano I, Dillner J. Concomitant human papillomavirus (HPV) vaccination and screening for elimination of HPV and cervical cancer. Nat Commun. 2024 May 1;15(1):3679. doi: 10.1038/s41467-024-47909-x.

Reference Type: DERIVED

PMID: 38693149 (View on PubMed)

Other Identifiers

Catch-up vaccination

Identifier Type: -

Identifier Source: org_study_id